PE20160040A1 - Nuevos compuestos inhibidores de la fosfodiesterasa del tipo 10a - Google Patents
Nuevos compuestos inhibidores de la fosfodiesterasa del tipo 10aInfo
- Publication number
- PE20160040A1 PE20160040A1 PE2015001893A PE2015001893A PE20160040A1 PE 20160040 A1 PE20160040 A1 PE 20160040A1 PE 2015001893 A PE2015001893 A PE 2015001893A PE 2015001893 A PE2015001893 A PE 2015001893A PE 20160040 A1 PE20160040 A1 PE 20160040A1
- Authority
- PE
- Peru
- Prior art keywords
- new type
- inhibiting compounds
- phosphodiesterase inhibiting
- cyc3
- cyc1
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 title abstract 2
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 title abstract 2
- 230000002401 inhibitory effect Effects 0.000 title 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 2
- 229910052717 sulfur Inorganic materials 0.000 abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- MQZSJAVVAPGAFD-UHFFFAOYSA-N 5-methyl-3-morpholin-4-yl-7-pyridin-4-ylthieno[2,3-d]pyridazin-4-one Chemical compound C1=2SC=C(N3CCOCC3)C=2C(=O)N(C)N=C1C1=CC=NC=C1 MQZSJAVVAPGAFD-UHFFFAOYSA-N 0.000 abstract 1
- 150000001204 N-oxides Chemical class 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 150000002431 hydrogen Chemical group 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Epidemiology (AREA)
Abstract
Compuestos de la formula I, los N-oxidos, tautomeros, y las sales farmaceuticamente aceptables de los mismos; que son inhibidores de la fosfodiesterasa tipo 10. Donde Q es O o S; X1 es N o CH; X2 es O o S; R1 es Y1-Cyc1; R2 es hidrogeno, halogeno, etc.; R3 es Y3-Cyc3, R4 es C1-C4 alquilo, etc.; Y1 , Y3 es enlace, CH2, etc.; Cyc1; Cyc3 son fenilo, etc. Compuestos preferidos son: 5-metil-3-(oxetan-3-ilamino)-7-(piridin-4-il)tieno[2,3-d]piridazin-4(5H)-ona; 5-metil-3-(morfolin-4-il)-7-(piridin-4-il)tieno[2,3-d]piridazin-4(5H)-ona
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361779141P | 2013-03-13 | 2013-03-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20160040A1 true PE20160040A1 (es) | 2016-02-11 |
Family
ID=50241454
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2015001893A PE20160040A1 (es) | 2013-03-13 | 2014-03-12 | Nuevos compuestos inhibidores de la fosfodiesterasa del tipo 10a |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US9200005B2 (es) |
| EP (1) | EP2970328B1 (es) |
| JP (1) | JP2016510786A (es) |
| KR (1) | KR20150127724A (es) |
| CN (1) | CN105358561A (es) |
| AR (1) | AR095267A1 (es) |
| AU (1) | AU2014230825A1 (es) |
| BR (1) | BR112015022094A2 (es) |
| CA (1) | CA2902654A1 (es) |
| CL (1) | CL2015002545A1 (es) |
| CR (1) | CR20150496A (es) |
| DO (1) | DOP2015000214A (es) |
| HK (1) | HK1219273A1 (es) |
| IL (1) | IL240593A0 (es) |
| MX (1) | MX2015012389A (es) |
| PE (1) | PE20160040A1 (es) |
| PH (1) | PH12015501962A1 (es) |
| RU (1) | RU2015143536A (es) |
| SG (1) | SG11201507380PA (es) |
| TW (1) | TW201441230A (es) |
| UY (1) | UY35393A (es) |
| WO (1) | WO2014140086A1 (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2852054T3 (es) | 2013-03-15 | 2021-09-10 | Global Blood Therapeutics Inc | Compuestos y usos de los mismos para la modulación de hemoglobina |
| EA202092627A1 (ru) | 2013-11-18 | 2021-09-30 | Глобал Блад Терапьютикс, Инк. | Соединения и их применения для модуляции гемоглобина |
| JP6767969B2 (ja) | 2014-09-05 | 2020-10-14 | ジェネンテック， インコーポレイテッド | がんの処置における使用のためのｐｃａｆおよびｇｃｎ５阻害剤としての式（ｉ）のフタラジン誘導体 |
| CN107074823B (zh) | 2014-09-05 | 2021-05-04 | 基因泰克公司 | 治疗性化合物及其用途 |
| CN107406429B (zh) | 2015-01-09 | 2021-07-06 | 基因泰克公司 | 哒嗪酮衍生物及其在治疗癌症中的用途 |
| CN111182898B (zh) * | 2017-06-28 | 2024-04-16 | Ptc医疗公司 | 用于治疗亨廷顿氏病的方法 |
| CN115838364A (zh) * | 2022-12-20 | 2023-03-24 | 河南沁朋科技有限公司 | 一种3,3-双噻吩的合成方法 |
| TW202506660A (zh) * | 2023-04-27 | 2025-02-16 | 美商塞普特納公司 | Mrgprx2拮抗劑及其使用方法 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TR200001603T2 (tr) | 1997-12-05 | 2000-10-23 | Astrazeneca Uk Limited | Yeni bileşikler |
| US20030032579A1 (en) | 2001-04-20 | 2003-02-13 | Pfizer Inc. | Therapeutic use of selective PDE10 inhibitors |
| SE0300120D0 (sv) * | 2003-01-17 | 2003-01-17 | Astrazeneca Ab | Novel compounds |
| CA2534432A1 (en) | 2003-07-31 | 2005-02-10 | Bayer Pharmaceuticals Corporation | Methods for treating diabetes and related disorders using pde10a inhibitors |
| MXPA06014236A (es) | 2004-06-07 | 2007-02-14 | Pfizer Prod Inc | Inhibicion de la fosfodiesterasa 10 como tratamiento para las afecciones relacionadas con el sindrome metabolico y con la obesidad. |
| AU2005282721A1 (en) | 2004-09-03 | 2006-03-16 | Memory Pharmaceuticals Corporation | 4-substituted 4, 6-dialkoxy-cinnoline derivatives as phospodiesterase 10 inhibitors for the treatment of psychiatric or neurological syndroms |
| AU2006279548A1 (en) | 2005-08-16 | 2007-02-22 | Amgen, Inc. | Phosphodiesterase 10 inhibitors |
| NL2000397C2 (nl) | 2006-01-05 | 2007-10-30 | Pfizer Prod Inc | Bicyclische heteroarylverbindingen als PDE10 inhibitoren. |
| WO2007082546A1 (en) | 2006-01-20 | 2007-07-26 | H. Lundbeck A/S | Use of tofisopam as a pde10a inhibitor |
| US20100222353A1 (en) | 2006-01-27 | 2010-09-02 | Pfizer Products Inc. | Aminophthalazine derivative compounds |
| MX2008010668A (es) | 2006-02-21 | 2008-10-01 | Amgen Inc | Derivados de cinolina como inhibidores de fosfodiesterasa 10. |
| MX2008010671A (es) | 2006-02-21 | 2008-10-01 | Amgen Inc | Derivados de cinolina como inhibidores de fosfodiesterasa 10. |
| EP1996587A1 (en) | 2006-02-23 | 2008-12-03 | Pfizer Products Incorporated | Substituted quinazolines as pde10 inhibitors |
| US20070287707A1 (en) | 2006-02-28 | 2007-12-13 | Arrington Mark P | Phosphodiesterase 10 inhibitors |
| US20070265258A1 (en) | 2006-03-06 | 2007-11-15 | Ruiping Liu | Quinazoline derivatives as phosphodiesterase 10 inhibitors |
| AU2007223801A1 (en) | 2006-03-08 | 2007-09-13 | Amgen Inc. | Quinoline and isoquinoline derivatives as phosphodiesterase 10 inhibitors |
| TW200817400A (en) | 2006-05-30 | 2008-04-16 | Elbion Ag | Pyrido [3,2-e] pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them |
| TW200815436A (en) | 2006-05-30 | 2008-04-01 | Elbion Ag | 4-amino-pyrido[3,2-e]pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them |
| CA2654394A1 (en) | 2006-06-26 | 2008-01-03 | Pfizer Products Inc. | Tricyclic heteroaryl compounds as pde10 inhibitors |
| US20080090834A1 (en) | 2006-07-06 | 2008-04-17 | Pfizer Inc | Selective azole pde10a inhibitor compounds |
| SI2057153T1 (sl) | 2006-07-10 | 2012-12-31 | H. Lundbeck A/S | (3-ril-piperazin-1-il) derivati 6,7-dialkoksikuinazolin, 6,7-dialkoksiftalazin in 6,7-dialkoksiizokuinolin |
| WO2008020302A2 (en) | 2006-08-17 | 2008-02-21 | Pfizer Products Inc. | Heteroaromatic quinoline-based compounds as phosphodiesterase (pde) inhibitors |
| US20090062277A1 (en) | 2007-08-21 | 2009-03-05 | Essa Hu | Phosphodiesterase 10 inhibitors |
| US20090062291A1 (en) | 2007-08-22 | 2009-03-05 | Essa Hu | Phosphodiesterase 10 inhibitors |
| WO2009029214A1 (en) | 2007-08-23 | 2009-03-05 | Amgen Inc. | Isoquinolone derivatives as phosphodiesterase 10 inhibitors |
| TW200918519A (en) | 2007-09-19 | 2009-05-01 | Lundbeck & Co As H | Cyanoisoquinoline |
| WO2009068320A1 (en) | 2007-11-30 | 2009-06-04 | Elbion Gmbh | Aryl and heteroaryl fused imidazo (1,5-a) pyrazines as inhibitors of phosphodiesterase 10 |
| WO2009068246A2 (en) | 2007-11-30 | 2009-06-04 | Elbion Gmbh | Methods of treating obesity and metabolic disorders |
| CN101918408A (zh) | 2007-11-30 | 2010-12-15 | 惠氏有限责任公司 | 作为磷酸二酯酶10的抑制剂的芳基和杂芳基稠合的咪唑并[1,5-a]吡嗪 |
| US20090143361A1 (en) | 2007-11-30 | 2009-06-04 | Elbion Gmbh | Pyrido[3,2-E]Pyrazines, Process For Preparing The Same, And Their Use As Inhibitors Of Phosphodiesterase 10 |
| US8389567B2 (en) * | 2007-12-12 | 2013-03-05 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| US8927718B2 (en) * | 2009-08-26 | 2015-01-06 | Takeda Pharmaceutical Company Limited | Fused heterocyclic ring derivative and use thereof |
| EP2632461A4 (en) | 2010-10-29 | 2014-04-02 | Merck Sharp & Dohme | Isoindolinone PDE10 INHIBITORS |
| US9938269B2 (en) | 2011-06-30 | 2018-04-10 | Abbvie Inc. | Inhibitor compounds of phosphodiesterase type 10A |
| US20130116241A1 (en) | 2011-11-09 | 2013-05-09 | Abbvie Inc. | Novel inhibitor compounds of phosphodiesterase type 10a |
-
2014
- 2014-02-25 US US14/189,961 patent/US9200005B2/en not_active Expired - Fee Related
- 2014-03-12 WO PCT/EP2014/054810 patent/WO2014140086A1/en not_active Ceased
- 2014-03-12 SG SG11201507380PA patent/SG11201507380PA/en unknown
- 2014-03-12 EP EP14709320.7A patent/EP2970328B1/en not_active Not-in-force
- 2014-03-12 KR KR1020157029132A patent/KR20150127724A/ko not_active Withdrawn
- 2014-03-12 CA CA2902654A patent/CA2902654A1/en not_active Abandoned
- 2014-03-12 AR ARP140100879A patent/AR095267A1/es unknown
- 2014-03-12 MX MX2015012389A patent/MX2015012389A/es unknown
- 2014-03-12 AU AU2014230825A patent/AU2014230825A1/en not_active Abandoned
- 2014-03-12 CN CN201480014146.XA patent/CN105358561A/zh active Pending
- 2014-03-12 RU RU2015143536A patent/RU2015143536A/ru unknown
- 2014-03-12 TW TW103108560A patent/TW201441230A/zh unknown
- 2014-03-12 JP JP2015562117A patent/JP2016510786A/ja active Pending
- 2014-03-12 UY UY0001035393A patent/UY35393A/es not_active Application Discontinuation
- 2014-03-12 PE PE2015001893A patent/PE20160040A1/es not_active Application Discontinuation
- 2014-03-12 HK HK16107260.0A patent/HK1219273A1/zh unknown
- 2014-03-12 BR BR112015022094A patent/BR112015022094A2/pt not_active IP Right Cessation
-
2015
- 2015-08-16 IL IL240593A patent/IL240593A0/en unknown
- 2015-09-03 DO DO2015000214A patent/DOP2015000214A/es unknown
- 2015-09-04 PH PH12015501962A patent/PH12015501962A1/en unknown
- 2015-09-09 CL CL2015002545A patent/CL2015002545A1/es unknown
- 2015-09-16 CR CR20150496A patent/CR20150496A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20140275069A1 (en) | 2014-09-18 |
| MX2015012389A (es) | 2016-03-03 |
| IL240593A0 (en) | 2015-09-24 |
| KR20150127724A (ko) | 2015-11-17 |
| PH12015501962A1 (en) | 2016-01-11 |
| BR112015022094A2 (pt) | 2018-06-12 |
| WO2014140086A1 (en) | 2014-09-18 |
| AR095267A1 (es) | 2015-09-30 |
| SG11201507380PA (en) | 2015-10-29 |
| CR20150496A (es) | 2016-02-19 |
| HK1219273A1 (zh) | 2017-03-31 |
| CN105358561A (zh) | 2016-02-24 |
| JP2016510786A (ja) | 2016-04-11 |
| AU2014230825A1 (en) | 2015-09-03 |
| RU2015143536A (ru) | 2017-04-18 |
| TW201441230A (zh) | 2014-11-01 |
| CA2902654A1 (en) | 2014-09-18 |
| EP2970328A1 (en) | 2016-01-20 |
| CL2015002545A1 (es) | 2016-07-22 |
| DOP2015000214A (es) | 2015-12-31 |
| UY35393A (es) | 2014-10-31 |
| EP2970328B1 (en) | 2017-04-26 |
| US9200005B2 (en) | 2015-12-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20160040A1 (es) | Nuevos compuestos inhibidores de la fosfodiesterasa del tipo 10a | |
| EP4247369A4 (en) | SPIROCYCLIC-SUBSTITUTED 6,7-DIHYDRO-PYRANO[2,3-D]PYRIMIDINE INHIBITORS OF THE KRAS G12C MUTANT | |
| NZ629025A (en) | Naphthyridine derivatives useful as alpha-v-beta-6 integrin antagonists | |
| PH12017502171A1 (en) | PYRIDO[3,4-d]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | |
| PE20191245A1 (es) | Compuestos de tiazolcarboxamidas y piridinacarboxamida utiles como inhibidores de quinasa pim | |
| MY204050A (en) | Benzolactam compounds as protein kinase inhibitors | |
| NZ626394A (en) | Substituted annulated pyrimidines and triazines, and use thereof | |
| PE20200388A1 (es) | Amidas heterociclicas de 5 miembros y biciclicas como inhibidores de rock | |
| EA201400182A1 (ru) | Производные пиридин-2(1н)-она в качестве ингибиторов jak | |
| TN2013000394A1 (fr) | Derives de pyrrolo [2,3-d] pyrimidine servant d'inhibiteurs de kinases apparentees a la tropomyosine | |
| NZ599040A (en) | 2,4-disubstituted pyrido[4,3-d]pyrimidin-5(6h)-one compounds for selective inhibitors of lrrk2 and syk kinases | |
| PE20190339A1 (es) | 1h-pirazolo[4,3-b] piridinas como inhibidores de pde1 | |
| PE20152033A1 (es) | Heterociclos bicicliclos como inhibidores de fgfr | |
| BR112014018528A8 (pt) | Derivados de pirido [2,3] pirimidina 2-amino, 6-fenil substituídos úteis como inibidores de raf quinase | |
| PE20141938A1 (es) | Nuevos compuestos inhibidores de la fosfodiesterasa del tipo 10a | |
| MX2021011389A (es) | Compuestos de imidazolonilquinolina y usos terapeuticos de los mismos. | |
| AR091285A1 (es) | Inhibidores de bromodominio y sus usos | |
| GEP20197050B (en) | Solid state forms of fused heteroaromatic pyrrolidinones | |
| ECSP109964A (es) | Pirimidinas bicíclicas fusionadas | |
| PE20141553A1 (es) | Compuestos de triazolopiridina como inhibidores de la ped10a | |
| PE20170008A1 (es) | Compuestos heteroaromaticos y su uso como ligandos de dopamina d1 | |
| BR112015032132A2 (pt) | cristais de base livre | |
| PE20170640A1 (es) | Derivados de quinolizinona como inhibidores de pi3k | |
| PE20170009A1 (es) | Compuestos heteroaromaticos y su uso como ligandos de dopamina d1 | |
| PE20151940A1 (es) | Derivados de triazina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD | Application declared void or lapsed |